Comparative Pharmacology
Head-to-head clinical analysis: MOMETASONE FUROATE versus SYMBICORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOMETASONE FUROATE versus SYMBICORT.
MOMETASONE FUROATE vs SYMBICORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mometasone furoate is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, reduced arachidonic acid release, and decreased synthesis of prostaglandins and leukotrienes. It also suppresses cytokines, chemokines, and adhesion molecules involved in inflammation.
Symbicort is a combination product containing budesonide, a corticosteroid, and formoterol fumarate dihydrate, a long-acting beta2-adrenergic agonist (LABA). Budesonide reduces inflammation by inhibiting inflammatory mediators and suppressing airway hyperresponsiveness. Formoterol stimulates beta2-adrenergic receptors in bronchial smooth muscle, leading to bronchodilation via increased cyclic AMP. The combination provides anti-inflammatory and bronchodilatory effects.
Inhaled: 110-880 mcg twice daily; Intranasal: 2 sprays (50 mcg/spray) per nostril once daily; Topical: Apply thin film to affected area once daily.
1-2 inhalations (80/4.5 mcg or 160/4.5 mcg) twice daily; maximum 2 inhalations twice daily of 160/4.5 mcg.
None Documented
None Documented
The terminal elimination half-life is approximately 5.8 hours (range 4.5–7.5 hours) following intravenous administration; after intranasal or inhalation use, the effective half-life supporting once-daily dosing is derived from receptor binding and local tissue retention.
Budesonide: 2–3 hours (terminal); Formoterol: 10 hours (terminal). Clinical context: Twice-daily dosing maintains bronchodilation.
Mometasone furoate is extensively metabolized in the liver; less than 1% of the dose is excreted unchanged in urine. The metabolites are primarily excreted in feces (~74%) via biliary elimination, with renal excretion accounting for approximately 8–10%.
Budesonide: 60% renal (as metabolites), 40% fecal; Formoterol: 60% renal (as metabolites), 40% fecal.
Category A/B
Category C
Topical / Inhaled Corticosteroid
Inhaled Corticosteroid/Long-Acting Beta Agonist